Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

<p>Figure 1.</p>
<p>The post <a href="https://forextv.com/top-news/pliant-therapeutics-announces-positive-safety-and-exploratory-efficacy-data-from-the-integris-psc-phase-2a-trial-of-bexotegrast-320-mg-in-patients-with-primary-sclerosing-cholangitis-and-sus/">Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>